Cowen Prime Advisors’s Gilead Sciences GILD Stock Holding History

Cowen Prime Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,500	Closed	-$176K	–	255
2015 Q2	$176K	Hold	1,500	–	–	0.07%	110
2015 Q1	$147K	Buy	+1,500	New	+$152K	0.06%	132
2014 Q4	–	Sell	-3,000	Closed	-$319K	–	320
2014 Q3	$319K	Hold	3,000	–	–	0.14%	85
2014 Q2	$249K	Hold	3,000	–	–	0.1%	80
2014 Q1	$213K	Hold	3,000	–	–	0.08%	94
2013 Q4	$225K	Buy	3,000 +1,000	+50%	+$69.6K	0.09%	92
2013 Q3	$126K	Sell	2,000 -1,000	-33%	-$59.8K	0.05%	141
2013 Q2	$155K	Buy	+3,000	New	+$156K	0.06%	119

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cowen Prime Advisors's GILD Position: Q3 2015 in Review

Cowen Prime Advisors sold out of Gilead Sciences (GILD) in Q3 2015, closing a stake of 1,500 shares — an estimated $176K sold.

Cowen Prime Advisors first reported a position in GILD in Q2 2013 and held it in 8 quarters. The position peaked at $319K in Q3 2014. 1,572 funds tracked by Wall St. Rank hold GILD as of Q3 2015.

Cowen Prime Advisors reported no remaining Gilead Sciences position as of Q3 2015 after selling out during the quarter.
Cowen Prime Advisors sold 1,500 Gilead Sciences shares in Q3 2015, an estimated $176K.
Cowen Prime Advisors first reported a position in Gilead Sciences in Q2 2013 and held it in 8 quarters.
Cowen Prime Advisors's Gilead Sciences position peaked at $319K in Q3 2014.
1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2015.

Based on Cowen Prime Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.